Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C20H22F2N4O2S.ClH |
Molecular Weight | 456.937 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CON(C)C(=O)N1N=C(S[C@@]1(CCCN)C2=CC=CC=C2)C3=CC(F)=CC=C3F
InChI
InChIKey=CTAIFVHCDONNPS-BDQAORGHSA-N
InChI=1S/C20H22F2N4O2S.ClH/c1-25(28-2)19(27)26-20(11-6-12-23,14-7-4-3-5-8-14)29-18(24-26)16-13-15(21)9-10-17(16)22;/h3-5,7-10,13H,6,11-12,23H2,1-2H3;1H/t20-;/m0./s1
DescriptionCurator's Comment: Description was created based on several sources, including
http://adisinsight.springer.com/drugs/800026254
Curator's Comment: Description was created based on several sources, including
http://adisinsight.springer.com/drugs/800026254
Filanesib is a highly selective, targeted KSP inhibitor with a mechanism of action distinct from currently available myeloma therapies such as immunomodulatory drugs (IMiDs®) and proteasome inhibitors. Across multiple studies, filanesib has demonstrated activity in heavily pretreated multiple myeloma patients, with a consistent safety profile including no drug-induced peripheral neuropathy and limited non-hematologic toxicity. Adverse events are generally limited to transient, non-cumulative and predominantly asymptomatic myelosuppression (decreases in blood counts) when supportive measures are used. Alpha 1-acid glycoprotein (AAG), a plasma protein, is a potential patient selection marker for filanesib. AAG is undergoing further investigation in clinical trials and could represent the first patient selection marker for a myeloma therapy. Filanesib is in Phase II for Multiple myeloma treatment.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL4581 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26396688 |
18.0 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27433944
intravenously either at a dose of 1.5 mg/m2 /day (schedule 1: days 1, 2, 15, and 16) or 3 mg/m2 /day (schedule 2: days 1 and 15).
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26396688
Filanesib inhibited His-tagged KSP motor domain assessed as inhibition of microtubule-stimulated KSP ATPase activity with IC50 18nM
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CHEMBL2347655
Created by
admin on Fri Dec 15 15:39:08 GMT 2023 , Edited by admin on Fri Dec 15 15:39:08 GMT 2023
|
PRIMARY | |||
|
300000044485
Created by
admin on Fri Dec 15 15:39:08 GMT 2023 , Edited by admin on Fri Dec 15 15:39:08 GMT 2023
|
PRIMARY | |||
|
CD-03
Created by
admin on Fri Dec 15 15:39:08 GMT 2023 , Edited by admin on Fri Dec 15 15:39:08 GMT 2023
|
PRIMARY | |||
|
72942033
Created by
admin on Fri Dec 15 15:39:08 GMT 2023 , Edited by admin on Fri Dec 15 15:39:08 GMT 2023
|
PRIMARY | |||
|
N98S79PF2I
Created by
admin on Fri Dec 15 15:39:08 GMT 2023 , Edited by admin on Fri Dec 15 15:39:08 GMT 2023
|
PRIMARY | |||
|
DBSALT001990
Created by
admin on Fri Dec 15 15:39:08 GMT 2023 , Edited by admin on Fri Dec 15 15:39:08 GMT 2023
|
PRIMARY | |||
|
C174959
Created by
admin on Fri Dec 15 15:39:08 GMT 2023 , Edited by admin on Fri Dec 15 15:39:08 GMT 2023
|
PRIMARY | |||
|
1385020-40-5
Created by
admin on Fri Dec 15 15:39:08 GMT 2023 , Edited by admin on Fri Dec 15 15:39:08 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD